A US-based KOL discusses segmentation and treatment decision-making in neuroendocrine tumors, including the role of surgery, observation and systemic therapy in unresectable disease. Topics include use and sequencing of somatostatin analogs, radioligand therapy and targeted agents, as well as insurance considerations. The interview also covers beta versus alpha emitters, retreatment strategies and interpretation of response rate data in emerging PRRT trials.

This interview was conducted on November 26, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.